Omeprazol Nt Ratiopharm (Omeprazole)

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

• Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition.
• Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication rates when used with antibiotics.
• NSA‑ID‑induced ulcer prophylaxis: lowers the risk of ulcer development in patients requiring long‑term NSAID therapy.

• Omeprazole selectively and irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid secretion, it markedly reduces both basal and stimulated gastric acid output, allowing the gastric mucosa to heal and maintaining a higher gastric pH.

Adverse reactions to omeprazole vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea or vomiting: transient gastrointestinal upset.
• Abdominal pain or discomfort: occasional cramping.
• Flatulence: excess gas production.
• Constipation: infrequent bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis risk.
• Acute interstitial nephritis: kidney inflammation.
• Hypomagnesemia: low serum magnesium levels.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
• Liver enzyme elevation: potential hepatic impact.
• Bone fracture risk: possible reduction in bone density with long‑term use.

When using Omeprazol Nt Ratiopharm, consider the following safety measures:

• Assess renal function: adjust use in severe impairment.
• Evaluate hepatic function: use with caution in liver disease.
• Review long‑term therapy need: limit duration to the shortest effective period.
• Monitor for vitamin B12 deficiency: prolonged acid suppression may affect absorption.
• Counsel on potential drug‑nutrient interactions: e.g., reduced absorption of iron or calcium supplements.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Clopidogrel: omeprazole reduces its antiplatelet activation.
• Atazanavir: decreased absorption leading to sub‑therapeutic levels.
• Dasatinib: reduced plasma concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, requiring more frequent monitoring.
• Phenytoin: may lower phenytoin levels, necessitating dose adjustment.
• Methotrexate: increased exposure risk, especially at high doses.
• Digoxin: possible rise in serum digoxin concentrations.
• Rifampicin: may reduce omeprazole exposure, affecting acid control.